Ricky Goldwasser
Stock Analyst at Morgan Stanley
(3.82)
# 658
Out of 4,862 analysts
234
Total ratings
64.15%
Success rate
22.2%
Average return
Main Sectors:
Stocks Rated by Ricky Goldwasser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LH Labcorp Holdings | Maintains: Overweight | $270 → $283 | $261.12 | +8.38% | 16 | Jun 11, 2025 | |
| CNC Centene | Initiates: Overweight | $70 | $55.22 | +26.77% | 11 | Jun 9, 2025 | |
| UNH UnitedHealth Group | Maintains: Overweight | $563 → $374 | $313.53 | +19.29% | 17 | May 14, 2025 | |
| DOCS Doximity | Maintains: Equal-Weight | $71 → $60 | $55.92 | +7.30% | 10 | Apr 24, 2025 | |
| CRL Charles River Laboratories International | Maintains: Equal-Weight | $220 → $184 | $149.45 | +23.12% | 20 | Feb 5, 2025 | |
| LFST LifeStance Health Group | Reiterates: Overweight | $10 | $5.26 | +90.11% | 8 | Apr 22, 2024 | |
| GDRX GoodRx Holdings | Maintains: Equal-Weight | $8 → $5.5 | $4.37 | +25.86% | 9 | Nov 10, 2023 | |
| OSCR Oscar Health | Maintains: Equal-Weight | $5 → $7.5 | $13.95 | -46.24% | 6 | Aug 30, 2023 | |
| ALHC Alignment Healthcare | Maintains: Overweight | $19 → $12 | $14.94 | -19.68% | 8 | Aug 30, 2023 | |
| DGX Quest Diagnostics | Reiterates: Equal-Weight | $145 | $180.21 | -19.54% | 17 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $365 | $298.14 | +22.43% | 7 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $403 → $420 | $728.20 | -42.32% | 27 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $120 | $6.78 | +1,669.91% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $549 → $620 | $235.26 | +163.54% | 11 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $485 → $500 | $384.55 | +30.02% | 2 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $124 | $67.46 | +83.81% | 9 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $296 → $318 | $317.40 | +0.19% | 11 | Aug 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $70 | $161.41 | -56.63% | 17 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $43 → $39 | $11.39 | +242.41% | 15 | Jul 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $182 → $195 | $156.89 | +24.29% | 6 | Oct 21, 2020 |
Labcorp Holdings
Jun 11, 2025
Maintains: Overweight
Price Target: $270 → $283
Current: $261.12
Upside: +8.38%
Centene
Jun 9, 2025
Initiates: Overweight
Price Target: $70
Current: $55.22
Upside: +26.77%
UnitedHealth Group
May 14, 2025
Maintains: Overweight
Price Target: $563 → $374
Current: $313.53
Upside: +19.29%
Doximity
Apr 24, 2025
Maintains: Equal-Weight
Price Target: $71 → $60
Current: $55.92
Upside: +7.30%
Charles River Laboratories International
Feb 5, 2025
Maintains: Equal-Weight
Price Target: $220 → $184
Current: $149.45
Upside: +23.12%
LifeStance Health Group
Apr 22, 2024
Reiterates: Overweight
Price Target: $10
Current: $5.26
Upside: +90.11%
GoodRx Holdings
Nov 10, 2023
Maintains: Equal-Weight
Price Target: $8 → $5.5
Current: $4.37
Upside: +25.86%
Oscar Health
Aug 30, 2023
Maintains: Equal-Weight
Price Target: $5 → $7.5
Current: $13.95
Upside: -46.24%
Alignment Healthcare
Aug 30, 2023
Maintains: Overweight
Price Target: $19 → $12
Current: $14.94
Upside: -19.68%
Quest Diagnostics
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $145
Current: $180.21
Upside: -19.54%
Jul 14, 2023
Reiterates: Overweight
Price Target: $365
Current: $298.14
Upside: +22.43%
Jan 6, 2023
Maintains: Overweight
Price Target: $403 → $420
Current: $728.20
Upside: -42.32%
Jan 6, 2023
Maintains: Overweight
Price Target: $140 → $120
Current: $6.78
Upside: +1,669.91%
Oct 31, 2022
Maintains: Overweight
Price Target: $549 → $620
Current: $235.26
Upside: +163.54%
Oct 21, 2022
Maintains: Equal-Weight
Price Target: $485 → $500
Current: $384.55
Upside: +30.02%
Oct 11, 2022
Maintains: Overweight
Price Target: $127 → $124
Current: $67.46
Upside: +83.81%
Aug 17, 2022
Maintains: Overweight
Price Target: $296 → $318
Current: $317.40
Upside: +0.19%
Jul 14, 2022
Maintains: Overweight
Price Target: $74 → $70
Current: $161.41
Upside: -56.63%
Jul 6, 2022
Maintains: Underweight
Price Target: $43 → $39
Current: $11.39
Upside: +242.41%
Oct 21, 2020
Maintains: Overweight
Price Target: $182 → $195
Current: $156.89
Upside: +24.29%